Podcasts about standard of care

“Patients are waiting…”Those simple but profound words from Dr. Steve St. Onge set the tone for this conversation, and for why this work matters so deeply.Science has always fascinated me. I often joke that I'm not smart enough to be a scientist, but I have endless respect for the people who are, especially those who can take incredibly complex ideas and explain them in a way the rest of us can truly understand. This is why I know you're going to love my conversation with Dr. St. Onge. Steve is the Chief Business Officer at Clarametyx. Dr. St. Onge is a PharmD and MBA with more than 15 years of experience spanning clinical care, medical affairs, and leadership in biotechnology. What stands out most about Steve isn't just his impressive résumé, it's his ability to clearly explain the science, the strategy, and, most importantly, the urgency behind the work Clarametyx is doing.I first met Steve in person at the North American Cystic Fibrosis Conference (NACFC) in Seattle, where we had the opportunity to really connect and talk about Clarametyx's approach. Their work focuses on targeting biofilm-driven inflammation and progressive lung damage, an area of significant unmet need for people living with chronic respiratory diseases, including cystic fibrosis. In this conversation, Steve breaks down what biofilms are, why they're so difficult to treat, and how Clarametyx is thinking differently about tackling the inflammation and lung damage they cause.We also talk about the long road of drug development, the responsibility that comes with working in rare disease, and why the phrase “patients are waiting” isn't just a saying, it's a call to action. This episode is an honest, accessible, and hopeful look at science in motion, and at the people behind the research who are driven by the patients counting on progress.If you've ever wanted a clearer understanding of how innovative science moves from idea to impact—and why time matters so much, his is a conversation you won't want to miss. Please like, subscribe, and comment on our podcasts!Please consider making a donation: https://thebonnellfoundation.org/donate/The Bonnell Foundation website:https://thebonnellfoundation.orgEmail us at: thebonnellfoundation@gmail.com Watch our podcasts on YouTube: https://www.youtube.com/@laurabonnell1136/featuredThanks to our sponsors:Vertex: https://www.vrtx.comViatris: https://www.viatris.com/enRead us on Substack: https://substack.com/@lstb?utm_campaign=profile&utm_medium=profile-pageWatch our trailer of Embracing Egypt: https://youtu.be/RYjlB25Cr9Y

Cristina Saura Manich, MD, PhD - First-Line Treatment of HER2-Positive Metastatic Breast Cancer: Could Investigational Approaches Improve on Current Standard of Care?

Send a textRobert Hawkins from Aurum Group for a practical look at why the lab remains one of the most crucial pieces of modern dentistry—and how Aurum is evolving to meet the future.Marc and Robert unpack how the lab is more than “fabrication”: it's a clinical partner that impacts case planning, predictability, esthetics, materials selection, turnaround, and the final patient experience. As dentistry becomes more digital, the lab's role becomes even more important—bridging technology with real-world execution and quality control.They also explore a bigger shift happening right now: the growing intersection of medicine and dentistry. Robert shares how Aurum is leaning into that direction—including the development of an imaging centre designed to elevate diagnostic inputs, strengthen treatment planning, and help clinicians see more clearly before they treat.From there, they dig into how labs are streamlining workflows, improving communication, and reducing friction from intake to delivery. Robert breaks down what's real (and what's not yet) with emerging tech like 3D printed crowns, where ceramics still lead, and how innovation is being applied responsibly—not just for speed, but for outcomes.You'll also hear about Aurum's investment in training and collaboration through the Hyo Maier Centre for Dental Excellence and hands-on “Innovation Tours” designed to strengthen digital workflows between practices and technicians. If you want a grounded, forward-looking conversation about where labs—and dentistry—are headed, this one's for you.Support the showThanks so much for watching and being part of the Dentist on Demand community—your support means everything. If you enjoyed this episode, make sure to follow us on social and share it with a friend or colleague who'd get value from it. We've got more real-world dental marketing and practice growth insights coming your way, so stay tuned—and we'll see you in the next one. Instagram: https://www.instagram.com/dentistondemand/ Facebook: https://www.facebook.com/dentistondemand.ca/ LinkedIn: https://www.linkedin.com/company/dentist-on-demand YouTube: https://www.youtube.com/channel/UCRTD4frcgfhZfklxl4JNT-g Threads: https://www.threads.com/@dentistondemand

I'm thrilled to share this conversation with my friend and colleague, Dr. Jaime Knopman, a reproductive endocrinologist and author of the newly released book Own Your Fertility. Dr. Knopman brings clarity, honesty, and courage to the conversations our patients need now more than ever. In this episode, are talking fertility-doctor-to-fertility-doctor about egg freezing, IVF success rates, and fertility preservation strategies. If you're wondering when to freeze your eggs, how age affects fertility, or what "fertility tests" actually tell you, this conversation is for you. Read the full show notes on Dr. Aimee's website. We dive deep into the science of fertility decline, debunk common myths about getting pregnant, and discuss practical steps for fertility preservation. Dr. Knopman shares her powerful "fertility puzzle" and "fertility treatment ladder" frameworks that help patients understand their options. We also cover the emotional aspects of infertility, pregnancy loss, and how to build resilience through your fertility journey. In this episode, we cover: Why fertility declines at age 32 and what AMH testing really tells you Egg freezing success rates and how many eggs you actually need The truth about monthly pregnancy chances (hint: it's not 50/50) IVF treatment options explained: from IUI to embryo transfer Fertility myths debunked: hormone balancing, ovulation tracking, and the "fertility test" How to talk to your doctor about fertility preservation and family planning Real patient success story: 10 frozen eggs, 1 embryo, 1 healthy baby Resources: Dr. Jaime Knopman's book: Own Your Fertility (on Amazon) Dr. Jaime Knopman Instagram Dr. Jaime Knopman website Do you have questions about IVF? Click here to join Dr. Aimee for The IVF Class. The next live class call is on Monday, February 9, 2026, at 4 pm PST, where Dr. Aimee will explain IVF and Egg Freezing, and there will be time to ask her your questions live on Zoom. Other ways to follow Dr. Aimee: Visit my YouTube channel for more fertility tipsSubscribe to the newsletter to get updatesJoin The Egg Whisperer SchoolRequest a Consultation with Dr. Aimee   Dr. Aimee Eyvazzadeh is one of America's most well‑known fertility doctors. Her success rate at baby‑making gives future parents hope when all hope is lost. She pioneered the TUSHY Method and BALLS Method to decrease your time to pregnancy. Learn more about the TUSHY Method and find a wealth of fertility resources at www.draimee.org.

Send us a text

Dr. Pedro Barata and Dr. Ravin Garg discuss strategies to increase trial representation, including leveraging trial navigators and prioritizing pragmatic trial models, as featured in the ASCO Educational Book article, "Practical Guide to Clinical Trial Accessibility: Making Trial Participation a Standard of Care." TRANSCRIPT Dr. Pedro Barata: Hello, and welcome to By the Book, a podcast from ASCO featuring compelling perspectives from authors and editors of the ASCO Educational Book. I'm Dr. Pedro Barata. I am a medical oncologist at University Hospital Seidman Cancer Center and an associate professor of medicine at Case Western Reserve University in Cleveland, Ohio. I am also the associate editor of the ASCO Educational Book. We know that in recent years, the oncology community has increasingly prioritized the need to modernize clinical trial eligibility, reduce patient burden, and enhance diversity in trial participation. On that note, today we will be speaking about ways to enhance access to clinical trials with Dr. Ravin Garg. He is a hematologist oncologist at Maryland Oncology Hematology and also an assistant professor of oncology at Johns Hopkins Hospital in Baltimore. Dr. Garg is also the co-author of a fantastic paper in the ASCO Educational Book titled, "Practical Guide to Clinical Trial Accessibility: Making Trial Participation a Standard of Care."  Dr. Garg, welcome. Thanks for being here, and congrats on your paper. Dr. Ravin Garg: Thank you for having me, Pedro. I am excited to be here. Dr. Pedro Barata: [KI1]  Your paper is a wonderful, multidisciplinary piece that actually features perspectives from the different stakeholders, right? The patient advocacy, industry, community practice, and academia about these challenges in making trials more available. This podcast is a wonderful platform. It reaches out to a lot of folks within our community. So, I will start by asking you the obvious. Why do you think it is a must read for our community, for our listeners? Dr. Ravin Garg: So Pedro, thanks again for inviting me. You do a great job with these podcasts.  So, I think first and foremost, oncologists right now are under a lot of stress, just in terms of clinical volume. There is concern for research money, and how we get the best care for our patients. So I think this article is very important because it helps bring together, as you had mentioned, the stakeholders throughout academic to community practice and everywhere in between, and try to find how, as a team with different oncologists who partake in different aspects of oncology, can come together to streamline the process to try to get our patients on trials, or certainly have them have availability of trials, just if they are interested in going on them. Being in practice, we have had several challenges that we can talk about throughout this podcast, but I think it is a very important paper because it recognizes that at the end of the day, it takes a team effort for all of us in academics, community, industry, and pharmaceuticals to really come together as a team to really help put forth the trials for our patients. Dr. Pedro Barata: So, from the perspective of a community oncologist, how do you put together, or maybe you can describe some of the challenges that you see to increase trial participation in the community? Dr. Ravin Garg: Yes, Pedro, that is a great question, and it is something that I keep on thinking about and trying to find ways to be better at it myself. But I will say some of the challenges as a community doctor that I have seen for myself and talking to other colleagues. Number one, I do think there is a lot of stress on doctors in the community in general, Pedro. Oftentimes we are tasked to see a wide smorgasbord of patients, so we may not have the luxury of being a specialist in any particular tumor subtype. Like oftentimes, we will have to see lung cancer, the next one will be breast cancer, the next one could be CML, the next one could be thrombocytopenia. And as you know better than I do, Pedro, the field in each one of these disciplines is changing so rapidly: molecular genomics, radioligand treatments, different imaging tests, MRD testing for some of our hematologic malignancies. And I think one challenge we have in community is just keeping up with the basics of Oncology 101. In the process of doing that, it can be very difficult to sometimes remember that we have very exciting trials available for our patients. So, I think a lot of it is the day in and day out of being an oncologist is so taxing at times that oftentimes a research trial is not the first thing in our head space when we see a patient. I think number two, Pedro, at least in the community, and perhaps this is with academics too, is that we are bombarded, I would say, by a lot of messaging these days. We have in-baskets to go through, labs to go through, things of that nature. And in the process of a patient visit, seeing them, doing an exam, taking a history, trying to go over the NCCN guidelines on best practice for how to manage their care, at least for me at times, it is very hard to remember, "Hey, there might be a great trial available, whether within our network or maybe partnering with an academic center." So getting through a day can be fraught with a lot of peril and just difficulties, I would say. And I would say number three, Pedro, at least as, you know, I am in a private practice where I do see a wide range of benign and malignant hematology and solid tumors, so I would not call myself a specialist. And I think the challenge with that, at least for trials, Pedro, is that when you are a specialist or perhaps you are focusing on a couple of disease subtypes, you become more of an authoritative voice in those types of tumors, and you might be more aware of the trials within your network or perhaps in proxy with an academic center that you can offer your patient. So I think when sometimes we spread ourselves too thin, it can be very hard to be a thought leader, if you will, in a particular subtype of a malignancy, let's say, and maybe not be aware of a trial that could be really well-suited for your patient. In terms of ideas that myself and colleagues have had in terms of helping mitigate against some of these, I would say, setbacks or issues in the practice for trial enrollment, some of the things we have talked about, Pedro, is, number one, is we do partner with academic centers. So we live here in Maryland. We have several really fantastic academic centers. So, you know, oftentimes, not just within our practice of Maryland Oncology Hematology, we have a lot of great trials available here too, for certain, but in addition to that, we will often times work with doctors at Georgetown, Johns Hopkins, and Maryland if they have a compelling trial that we do not have within our network. It is really of the patient's interest, Pedro, to reach out to them in a collaborative manner to see if they have a trial that might be really compelling for your patient. So I do find myself collaborating a lot with colleagues in, like talented like yourself in academics. You know, I think you do a lot of GU malignancies. So as an example, like partnering with colleagues who are GU experts and say, "Hey, we have a patient with stage IV renal cell. These are the standard options I know, but are there any trials that you might have available?" I think the other thing that has been very helpful for us is having navigators within research, Pedro. Like as an example, what has really helped the uptake of trial enrollment for our center in Annapolis is having a research navigator because often times what they can do is, a priori, Pedro, before you see the patient and you are kind of formulating a standard of care treatment plan perhaps, they might tug you on the shirt and say, "Hey, we have a great trial here through Sarah Cannon, or there might be something else out there." And being aware of that when you go into a patient's room really provides a nice arena, if you will, to go and say, "The standard of care is here, but hey, we have a trial option that might be well suited for you, maybe perhaps even better, that we can talk about, too." So having research support in the community is really a huge boon, I think, Pedro, for us to really increase our enrollment for patients onto trials. Dr. Pedro Barata: Yes, I really love that, Ravin. So, let me switch gears a bit. I would love for you to talk a little bit about patient advocacy because they do play a huge role in cancer, and they address many barriers. How do you think we should leverage the patient advocacy groups to reduce patient burden and maybe have them really leverage patient advocacies to improve representation in clinical trials? What do we think we can do more? Dr. Ravin Garg: Oh, Pedro, I think they are very critically important. As a clinical oncologist now, and I would say this is for anyone in the field of medicine, you are exactly right. I think patients are bombarded by information. There are a lot of things online, whether it be TikTok, Facebook, Google, Yahoo, and people really just have a lot of information given to them. And some of it is fact driven, and some of it is not, Pedro. And oftentimes, I do think there can be at times a mistrust with some medical personnel. I think we are in an era where we are seeing that to some degree with some attributes of medicine. And I think of it as an opportunity for education for the patient and for myself as a physician. And I think patient advocates, to your point, which was well taken, serve as a bridge to both. And what I mean is that, you know, patient advocates are wonderful. They are, I think, outstanding communicators. They almost are a neutral party, Pedro, where many patients feel that they are an independent source of information that is free of bias, if you will. They are there to provide support, emotional support, scientific support for patients so they can make an informed decision. So, in terms of our practice right now, patient advocates is something that we are evolving in that capacity, I would say, Pedro. I think now more than ever, having more people as bridges of communication with care providers along with patients is of critical importance. And I would venture a guess, and I think this has been published, where patient advocates really can help tremendously in familiarizing patients with trials and what they are all about and maybe clear up some misconceptions of what trials, what the mission of trials are. Because I do think some patients, at least I have had a few over the years, where when they hear the term trial, they almost think they are being experimented upon, when, in point of fact, they could really help advance their care. That messaging along the way for some can may be mixed up a little bit. And so I think patient advocates is a really great way to offer more information for patients with a source they find very independent and trustworthy, if you will. And it can really help expedite, and I think make a more fruitful conversation for care providers, whether academic or community, and they might be more open-minded in terms of enrolling onto a trial. Dr. Pedro Barata: Wonderful. Yes, I agree. I agree with you completely.  So let's focus a little bit now on the folks designing the studies. We usually call them the sponsors. It might be an academic sponsorship, if you will, but we can also have pharma being the sponsor of a study. The angle from an academic design, it is not necessarily the same as what happens when we have pharma. And from that angle, how do you think a more inclusive research can be promoted? Dr. Ravin Garg: Oftentimes with trials, I think keeping them simple, as simple as we can. And what I mean by that is, often times for trials, Pedro, even for care providers who are enrolling, it can be daunting when there are a lot of different things involved, particularly, let's say, for investigator sponsored, which are incredibly brilliant science, incredible, but it can be a little bit daunting for patients and even the referring physician to talk about getting translational specimens, imaging, traveling to certain centers to get scans and biopsies and even different diagnostic testing like PSMA testing for, you know, prostate cancer. And it can, I think, be very intimidating for patients in terms of what might be required of him or her to enter onto a trial. Like, "This is not what I signed up for. This is laborious. This is a full time job for me. Do I have to pay for parking to go to a city? Do I have to pay for these imaging tests? And do I have to stay in a place for my family to enroll onto a trial?" So I think keeping trials as simple as possible, but yet cull the data we need as investigators where we can really advance the care, hopefully get approval for a drug, but also learn more about the medication and how it works for our patients. So I think simplifying language for trial is very important. I know when I have gone over studies for patients, Pedro, if it is a voluminous amount of information, they can right away get very intimidated. "Like, oh my goodness, this is like a term paper for college again," you know? I am joking, but you know, keeping language simplified is very important, I think, number one. And I feel that sometimes when they are asked to do a lot of different diagnostic testing, which is very important for translational work, I 100% understand, but I do think sometimes patients can get a little bit off put, if you will, and frustrated with the whole process of doing it. The second thing for our patients, Pedro, that they have mentioned to us when we put them on trials, not just within our own site but elsewhere, is that it takes a lot of time in terms of collecting information, perhaps a washout period from their last standard of treatment prior to enrollment onto a study. Many patients, Pedro, as you know better than I do, are in maybe crisis in terms of their health and their cancer might be growing, promulgating out of control, and they worry about not being able to expeditiously start onto a treatment, onto a trial. So that can lead to a lot of frustration. And one thing that you brought up, which was outstanding for me, is the enrollment criterion for some of our patients is felt to be somewhat strict. We have had some patients who may have had a remote history of a stage I malignancy that was by all accounts in remission, you know, let's say 4 or 5 years in the past, and the risk of recurrence at this point would be incredibly low, but they may not be able to enter onto a study because of some stringent criterion put forth. And that can be a little bit frustrating. In fact, I have had one or two patients who, as an example, with kidney issues, but the GFR was about 60, like right near a cutoff that oftentimes, as you know, we use where you can get into trial or not. And you know, if they are at 58, as an example, and otherwise they are a picture of health, a great candidate for a trial that will likely advance their care, and if the entry criterion is too stringent, that might be a lost opportunity for all parties involved, all stakeholders, if you will. I do appreciate the criterion for entry onto studies cannot be too liberalized. You have to have a certain baseline, but there is a little bit of a gray area and tension, of sorts, if you will, where the patient has a comorbid illness that is a disqualifying offense, but in practicality, perhaps it shouldn't be, especially if they are motivated and there is an opportunity to really advance their care. We have run into, not often, but sometimes in the past, I should say, where patients have been very off put because we try to get them onto a study and there may have been a particular feature or attribute in their underlying care that they couldn't get onto it. So I think having a little bit more thoughtfulness, perhaps, in terms of entry criterion and practicality, if you will, I think would really help enrollment onto studies. Dr. Pedro Barata: Really well said. Is there anything else that you would like to tell our listeners before we wrap up the podcast today? Dr. Ravin Garg: I would say just macroscopically speaking, it is really an honor to be an oncologist. I think I speak for both of us. Anyone listening who is thinking about the field, it is tremendous. Just the research, the bravery of our patients, and the thoughtfulness of our scientists like Pedro and translationalists and clinical trialists is really awe inspiring. So I have really loved this field. I will say from a trial perspective, we really need to enter as many patients as we can onto trials because the science is so brilliant now, the genomic underpinnings of the tumor, we are making great strides as a team of clinicians and scientists, translationalists. So the more that we can get people onto trials and get approved drugs, it is going to help them out in the end. So I think it is such an important time for all of us to come together as a community, find the best way to help our patients out. And clinical trials have to be at the forefront of how we can continue to advance care for our patients. Dr. Pedro Barata: Yeah, no Ravin, I really agree with you. We really need to increase access to clinical studies, and actually your paper is a great step in that direction by raising awareness, bringing up solutions, and again, collaboration, collaboration, collaboration is really a multidisciplinary effort to accomplish that.  Thank you so much for sharing your fantastic thoughts and insights with us. Dr. Ravin Garg: Thank you, Pedro. I am- you do a wonderful job with these podcasts. I am really honored to meet you and to be part of this. Dr. Pedro Barata: And thank you to our listeners for your time today. I encourage you to check out Dr. Garg's article in the 2025 ASCO Educational Book. We will post a link to the paper in our show notes. And please join us again next month on By the Book for more insights on key advances and innovations that are shaping modern oncology. Thank you for your attention. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:          Dr. Pedro Barata   @PBarataMD    Dr. Ravin Garg Follow ASCO on social media:          @ASCO on X      ASCO on Bluesky     ASCO on Facebook       ASCO on LinkedIn       Disclosures:       Dr. Pedro Barata:   Stock and Other Ownership Interests: Luminate Medical   Honoraria: UroToday   Consulting or Advisory Role: Bayer, BMS, Pfizer, EMD Serono, Eisai, Caris Life Sciences, AstraZeneca, Exelixis, AVEO, Merck, Ipson, Astellas Medivation, Novartis, Dendreon   Speakers' Bureau: AstraZeneca, Merck, Caris Life Sciences, Bayer, Pfizer/Astellas   Research Funding (Inst.): Exelixis, Blue Earth, AVEO, Pfizer, Merck    Dr. Ravin Garg: Patents, Royalties, Other Intellectual Property: Creator, editor, and writer of hemeoncquestions.com  

Join Liz and Rachel as they debrief the conversation with Becky Lai on the journey to standard of care. They dive into best practices for using training to drive adoption, engage KOLs, and create a respected brand.In 2025, we're embarking on a MedDevice Training Journey: From clinical trials to standard of care. Join us all year long as we explore training at each stage of the product life cycle.Need help developing your clinical trial training strategies? Contact us at training@cumbyconsulting.com.Related Resources:https://open.spotify.com/episode/7DjeuGhXtiKaOM0qRoWC46?si=_wI8T6TkQ--ZsIoG2MgzmgSubscribe to our newsletter to hear more about the journey from clinical trials to standard of care! Click here to subscribe! Connect with us on LinkedIn:   ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Cumby Consulting⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Rachel Medeiros⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Liz Cumby⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠About Cumby Consulting:   Cumby Consulting's team of professionals deliver innovative MedTech training services for physicians, sales representatives, teaching faculty, key opinion leaders and clinical development teams. Whether you need a complete training system developed to deliver revenue sooner or a discrete training program for a specific meeting, Cumby Consulting will deliver highly strategic, efficient programs with uncompromising standards of quality.

In this fast paced conversation, Ken and Alex discuss the role of annual family meetings as an important part of a family's Legacy work. In this approach to doing Family Legacy, the Family Meeting represents a great opportunity for the advisor to work more closely with family members that they may have never connected with before. Not just the "Next Generation" clients, the annual Family Meeting gives the advisor a chance to work more closely with the spouse who may be highly interested in creating a meaningful family experience. One of the key ideas that emerged from the conversation was the role of an annual Family Meeting in helping families "develop the muscles" they will need to have in place when difficult decisions need to be made. By starting with a simple and fun Family Meeting experience and committing to a meeting every year the family benefits from learning how to work together, grapple with important decisions and experiencing the value of their financial advisor as an important, multi-generational resource. Also in this episode, the AllianceBernstein Digital Coach – see practice management solutions for advisor success: abfunds.com/go/digitalcoach DISCLAIMER Note to All Readers: The information contained here reflects the views of AllianceBernstein L.P. or its affiliates and sources it believes are reliable as of the date of this podcast. AllianceBernstein L.P. makes no representations or warranties concerning the accuracy of any data. There is no guarantee that any projection, forecast or opinion in this material will be realized. Past performance does not guarantee future results. The views expressed here may change at any time after the date of this podcast. This podcast is for informational purposes only and does not constitute investment advice. AllianceBernstein L.P. does not provide tax, legal or accounting advice. It does not take an investor's personal investment objectives or financial situation into account; investors should discuss their individual circumstances with appropriate professionals before making any decisions. This information should not be construed as sales or marketing material or an offer or solicitation for the purchase or sale of any financial instrument, product or service sponsored by AllianceBernstein or its affiliates.

Escaping "Half Truths" of the Medical Industry with Dr. Joseph JackoTIMESTAMPS:00:00 Intro Snip00:57 Introduce Dr. Joseph Jacko author of Bamboozled, Duped, and Hoodwinked02:10 How does Dr. Jacko still have a license considering he is exposing things in medicine05:20 Dr. Haley reads some surprising content from Dr. Jacko's book regarding the 100% risk reduction of a vaccine07:57 Why did medical doctors push the Covid vaccine considering the actual risk reduction?09:39 How smart are medical doctors?11:00 What is the purpose of a medicine? Do they cure anything?14:00 What should the goal of medicine be?14:58 What is the reason most doctors don't give lifestyle advice?15:35 Why don't we have time to spend with our patients?17:32 Dr. Haley explains why healthcare has gotten more expensive and explains the concept he sent to President Obama.21:07 Why doesn't Dr. Jacko take health insurance anymore?22:30 Dr. Haley explains how his study of drug advertising on TV demonstrated how people are exposed to 3 to 5 thousand drug advertisements per year on TV alone.24:10 Who is controlling the people's beliefs that drugs are the answer?25:20 Where does the FDA get their funds from?26:03 Who else are pharmaceutical companies funding and likely influencing?29:20 What medicine does Dr. Jacko take?30:35 What does the science say about aloe vera and cancer?32:00 What does Dr. Joseph Jacko do in his practice?34:39 What is Mainstream Medicine? 35:27 What medications can actually contribute to longevity?36:30 Does insurance pay for actual "Health Care"?37:37 What criteria do you use when choosing which vaccines to get?41:05 How does "Standard Of Care" affect what doctors do?42:26 Why might some doctors not allow patients return when they refuse vaccines?43:28 What power words were spoken to you?45:20 What is the "Top 40 Not So Wacko Jacko Rules Of Medicine"

Liz is joined on the podcast by Becky Lai, Chief Strategist and VP of Marketing, to talk about the true North Star of commercialization: standard of care. Their discussion reframes success as more than building a product—it's about building a market where the product is trusted, adopted, and indispensable. Together, they explore how purposeful training, meaningful KOL engagement, and a clear strategic vision accelerate adoption and move technologies from launch to lasting impact.In 2025, we're embarking on a MedDevice Training Journey: From clinical trials to standard of care. Join us all year long as we explore training at each stage of the product life cycle.Need help developing your clinical trial training strategies? Contact us at training@cumbyconsulting.com.Related Resources:Rebecca Lai is the Chief Strategist and Marketing Executive at Rebecca Lai Consulting. She is a strategy and commercial executive with over 20 years of experience in medical and health technology companies, ranging from venture-backed startups to Fortune 200 corporations. As a dynamic strategic operator specializing in go-to-market, commercialization, and innovative business strategies, she has consistently driven double-digit growth and scaled new businesses with global impact. With a strong background in devices, diagnostics, and the digital transformation of healthcare, Rebecca has a proven track record of pioneering disruptive solutions across the continuum of care. Most recently, she was VP of Corporate Development and Strategy at iRhythm Technologies (NASDAQ:IRTC), a digital healthcare provider of cardiac monitoring services. She began her career at Medtronic (NYSE:MDT), where she held progressive global leadership roles in sales and marketing. Rebecca is recognized for her ability to navigate complexity and her data-driven, customer-centric approach to creating value and delivering cutting-edge products and services to patients worldwide. She holds a BSE and MSE in Bioengineering from the University of Pennsylvania and serves on the advisory board for Diversity by Doing Healthtech.Subscribe to our newsletter to hear more about the journey from clinical trials to standard of care! Click here to subscribe! Connect with us on LinkedIn: ⁠⁠⁠⁠⁠⁠⁠⁠⁠Rebecca Lai⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Cumby Consulting⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Rachel Medeiros⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Liz Cumby⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠About Cumby Consulting:Cumby Consulting's team of professionals deliver innovative MedTech training services for physicians, sales representatives, teaching faculty, key opinion leaders and clinical development teams. Whether you need a complete training system developed to deliver revenue sooner or a discrete training program for a specific meeting, Cumby Consulting will deliver highly strategic, efficient programs with uncompromising standards of quality.

Episode 063 | Today I'm bringing you an episode of The DermBiz Show in which I had the pleasure and opportunity of sharing some of my story and private practice journey.Show notes and audio content for this episode are courtesy of The DermBiz Show with Tony Jackson and Dr. Mercy Odueyungbo-Jackson, both of whom I can't wait to feature on this show! If you like what you hear, please watch and follow their show. You won't regret it. You can check out the full video here: https://youtu.be/qaRvkHp6z8o?si=LaMrEXA_Y9mqnoeBRaising the Standard of Care with Dr. Stephen LewellisDo you feel constrained in a corporate environment? Do you believe there is a better way to treat patients than the assembly-line model? Then this episode is for YOU.In this episode, Dr. Stephen Lewellis shares his journey from a corporate job to building his own private practice. He explains why "the standard of care is table stakes" and how he is raising the bar by focusing on his Four Core Pillars. Dr. Lewellis shows you how to humanize the patient experience, where patients are so delighted they actually want to pay for it.He offers a unique perspective on starting a practice, reminding us that building a business is "not med school hard" and that success comes down to having a sustained "WHY" to drive you forward.

Is Your Chiropractic Care Plan a Sales Pitch or a Health Strategy? Understanding the Difference | The Prime Podcast Have you ever left a doctor's office with a recommended care plan and felt a wave of skepticism? It's a common experience, especially in chiropractic, where the purpose behind a structured plan is one of the most misunderstood aspects of care. Patients often turn to social media forums, asking friends, "Does this seem right?" creating a massive gray area filled with confusion and misinformation. In Episode 343 of The Prime Podcast, Dr. Skip and Dr. Julie Wies pull back the curtain on this "taboo" topic. They explore why the concept of a care plan is so divisive and why clear communication between a doctor and a patient is the most critical factor for a successful health outcome. This episode is an essential guide for any patient who wants to feel empowered and confident in their healthcare decisions. The doctors break down the two fundamental philosophies of care you'll encounter: Symptomatic Care: The reactive, "quick fix" approach. This is for when you just want immediate pain relief for a headache or back pain and have no long-term goals. Vitalistic Care: The proactive, wellness-focused approach. This is for patients who want to address the root cause of their issues, prevent them from recurring, and achieve a higher standard of overall health. Using a brilliant "fruit salad vs. veggie salad" analogy, Dr. Skip and Dr. Julie illustrate what happens when a patient's expectations don't align with a doctor's standard of care. They discuss why a chiropractor who is truly invested in your long-term wellness will always recommend a plan, and why "just come in when it hurts" can lead to a cycle of recurring problems and the false belief that "chiropractic didn't work." Furthermore, they tackle the thorny issue of insurance, explaining why the best chiropractors are often out-of-network and why that should be seen as a green flag indicating a commitment to wellness over "sick care." KEY TAKEAWAYS Communication is Key: A successful healthcare experience depends on the patient and doctor being on the same page with their goals and expectations before care begins. Vitalistic vs. Symptomatic: Understand which philosophy your chiropractor follows. Are they focused on proactive wellness and fixing the root cause (vitalistic), or just reactive pain relief (symptomatic)? A Care Plan is a Standard of Care: A structured care plan is not a sales pitch; it is a doctor's professional recommendation based on your history, exam, and health goals to achieve lasting results. Don't Ask the Internet, Ask Your Doctor: If you have questions about your care plan, the most qualified person to answer them is the doctor who created it based on your specific case. Insurance Doesn't Dictate Health: The best healthcare providers often operate outside of insurance networks because they refuse to let a third party dictate a standard of care that is focused on sickness, not wellness.

Dr. Mark Boldt has been a successful Prosthodontist for many decades, with a fantastic local reputation and known for having a high standard of care. He shares lessons learned over his career, thoughts on analog/digital workflows, his trusted dental lab tips and so much more. Ladies & Gentlemen, you're listening to "Confessions From A Dental Lab" and we're happy you're here. Subscribe today and tell a friend so we can all get 1% better :)Connect with Dr. Boldt on instagram at @markaboldtdds and email him at m-boldt@sbcglobal.netFollow KJ & NuArt on Instagram at @lifeatnuartdental, you can also reach us via email: kj@nuartdental.comLearn more about the lab and request information via our website: https://nuartdental.com/contactAsk us about our scanner program!

Today, the legal technology sector is experiencing an unprecedented surge of capital and innovation. We are witnessing massive investments, such as Nexl's successful $35 million Series B funding round and over $250 million secured by plaintiff-focused AI platforms Eve and EvenUp to level the playing field for the plaintiffs' bar. This funding fuels the development of AI-driven growth platforms and potent solutions like Westlaw Advantage for unparalleled research efficiency and the emergence of hybrid AI law firms like Crosby. AI adoption is accelerating, dramatically improving efficiency, with individual users reporting substantial weekly time savings by automating tasks that range from legal research and contract drafting to internal firm operations and marketing content creation. However, this rapid technological shift is accompanied by significant professional and regulatory challenges. Law tech management platform Nexl nabs $35 million Series B2025-10-08 | Startup DailySome police departments are using AI to write reports2025-10-08 | Minnesota Public RadioTransform the Legal Function by Embracing Legal Data Intelligence IDC Sep 30, 2025 This IDC Perspective explores how legal data intelligence (LDI) is transforming legal functions by enabling legal teams to manage, analyze, and leverage vast volumes of dig2025-10-08 | MarketResearch.comThe ROI and future of AI in legal2025-10-08 | IManage.comSquire Patton Boggs Bolsters its Customs Tariffs and Trade Team with Senior Hire in Los Angeles2025-10-08 | Squire Patton BoggsClients Name the 32 Law Firms Best at Gen AI Litigation2025-10-08 | BTI ConsultingMake 2026 The Year You Start Your Law Firm2025-10-08 | My ShingleThe new public defender: Some are turning to ChatGPT to offer legal advice and win small claims cases2025-10-08 | AOL.com2025 LDO Index: Legal departments want better service enhancement, but success metrics don't always reflect priorities - Thomson Reuters Institute2025-10-08 | Thomson ReutersWith ‘Under Review,' Stanford Law Expands Its Podcast Lineup to Examine the Future of Law and Business2025-10-08 | Stanford Law SchoolNexl Bags $23m, Will Invest In Hires + Acquisitions2025-10-08 | Artificial LawyerHybrid AI Law Firm, Crosby, Raises $20m – Cooley Invests2025-10-08 | Artificial LawyerMeet Westlaw Advantage: The next generation AI legal research solution2025-10-08 | Legal.ThomsonReuters.comUS law school takes Genie AI to coach new generation of students2025-10-08 | Business Weekly UK3 Ways Lawyers Are Finding New Efficiencies With AI2025-10-08 | Above The LawHealthcare Law Careers Surge in 2025 — A Strategic Opportunity for Legal Professionals2025-10-08 | JDJournalAI Investments Surge as Legal Tech Startups Target Plaintiffs' Firms2025-10-08 | JDJournalEve Launches AI Intake Platform with Voice Agent for Plaintiffs' Firms2025-10-08 | LawSitesElevate Your Law Firm's Content Marketing Workflows: AI Tools Worth Exploring2025-10-08 | JD SupraClio founder talks $1B acquisition of vLex and upcoming Clio Cloud Conference2025-10-08 | ABA JournalAvoiding risk: AI's double-edged role in e-discovery2025-10-08 | ReutersLawyer AI Competence: Training Is Becoming Mandatory — But Lawyers Still Get Burned2025-10-08 | Articles, Tips and Tech for Law Firms and LawyersLaw Companies and Their Role in the Legal Market2025-10-08 | Elevate ServicesThese people ditched lawyers for ChatGPT in court2025-10-08 | NBC Bay AreaLucio Raises $5M in Funding2025-10-08 | FinSMEsLegal Innovators UK – Speaker Highlight: A&O Shearman's Helen Lightfoot2025-10-08 | Artificial LawyerState AI laws = economic, legal & security risks2025-10-08 | New York Daily NewsIntake Is Broken: Why Law Firms Can't Afford to Ignore AI2025-10-08 | Artificial LawyerItaly enacts Law No. 132/2025 on Artificial Intelligence2025-10-08 | Inside Tech Law

Ever wondered if X-rays are really necessary before a chiropractic adjustment? Or have you been told they're an optional, skippable step? In this vital episode of The Prime Podcast, Dr. Skip and Dr. Julie Wies tackle the growing misconception around spinal imaging and explain why skipping this step could put your health at risk. Many people seek chiropractic care for back pain, neck pain, or general wellness, but not all understand the importance of a proper diagnosis. An adjustment without a clear picture of your spinal health is just guesswork. Drs. Skip and Julie reveal what a trained chiropractor can see on an X-ray—from hidden fractures and dangerous pathologies to congenital abnormalities that could make a standard adjustment harmful. Discover why the X-ray and the chiropractic profession were born in the very same year and how this foundational tool is a non-negotiable "standard of care" for ensuring patient safety, achieving better results, and truly understanding the root cause of your health concerns. Don't let a practitioner gamble with your spine. Learn how to advocate for the highest standard of care. In this episode, you will learn: Why spinal X-rays are a foundational standard of care in chiropractic, not an upsell. The difference between "guessing" and "knowing" when it comes to your chiropractic adjustment. Real-life examples of serious conditions (cancer, aneurysms, hidden fractures) that were discovered through routine spinal imaging. A compelling case study of how an X-ray solved the mystery of a teenager's chronic migraines. The truth about radiation exposure from X-rays versus everyday activities like flying. What to do if your chiropractor has never taken an X-ray and how to find a practitioner who prioritizes your safety. Disclaimer: The content in this podcast is for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment.

On this episode of IPA's What, Why & How podcast, IPA CEO Matt Pitlick welcomes Anne Schlepphorst, Bureau Chief of Monitoring and Executive Director of the Iowa Board of Pharmacy, for an update from the Board, covering standard of care, immunizations, and more. Anne Schlepphorst serves as the Executive Director of the Iowa Board of Pharmacy, Interim Executive Director of the Iowa Board of Nursing, and Monitoring Bureau Chief. Anne has worked with the boards for the past seven years, most recently serving as the Chief Investigator for the Iowa Boards of Pharmacy and Medicine. When not working, Anne and her husband spend most of their time at the baseball field, hockey rink, wrestling mat, or football field watching their two teenage boys. Connect with us on LinkedIn: Anne Schlepphorst Matthew Pitlick Iowa Pharmacy Association

At the intersection of medical innovation and compassionate, community-centered care, Driscoll Children's Hospital has emerged as a national leader in pediatric heart care and health equity. In this episode of Healthcare Insider, Dr. Stephen M. Langley, medical director and chief of pediatric cardiac surgery at Driscoll Children's Hospital, shares powerful insights into how the hospital is elevating care for complex and underserved pediatric populations across south Texas. From groundbreaking outcomes in congenital heart surgeries to culturally informed, family-centered care models, Dr. Langley outlines how Driscoll is redefining “best care” for children and what other healthcare leaders can learn from their approach.

AI-Driven CMR: Where Gold Standard Becomes Standard of Care

Hey Girl! You know those moments that just make life feel so full circle? Well, that's what this episode felt like when I was interviewing my special guest for the show this week! Almost 8 yrs ago, I was just like you, searching instagram and social media for “Pelvic floor Exercises”, “Pelvic Floor Physical Therapy”, “Pregnancy Safe Exercises”,  “Prenatal Pelvic Floor” and more! Coming Fresh out of Grad school, pregnant with my second baby and now aware that Pelvic Floor PT exists and that guess what… I didn't need to pee my pants the last 6 years?! So I was motivated to keep my leaking from getting worse during the pregnancy and starting diving more into Pelvic Floor Health. At the time, I knew the “What” and some of the “Why” leaking and other pelvic issues occurred and that they were not normal, but I had yet to learn the “How” to fix it.     So after searching for reliable sources on social media (yes they exist but you have to do your research), I found the one and only Vaginal Whisperer, Dr. Sara Reardon. Wearing a Vulva costume and talking about taboo topics like poop and sex, she caught my attention immediately.  I started doing some of the exercises she talked about on her page and started to really see a difference and ultimately healed all of my incontinence! She was and is, a trailblazer for Pelvic health and Women's Health in general as she continues to educate, empower and support women all over the world while breaking down cultural barriers. With that being said, I am so thrilled to have Dr. Sara Reardon on the show this week to dive more into her story and how she continues to elevate the standard of care for women in the US and inspire clinicians (like me) to do the same!    Dr. Sara Reardon is a board-certified pelvic floor physical therapist with over 18 years of experience helping individuals prevent and overcome pelvic floor issues including, urinary leakage, painful sex, prolapse and discomfort during pregnancy, postpartum and menopause. Sara has been featured in Time, Yahoo, Harper's Bazaar, Romper, InStyle, Today, and numerous other podcasts, publications, and professional conferences about her advocacy and educational work as a pelvic floor therapist. She is also a TED presenter on Rethinking Postpartum Care. Sara is the Founder of The V-Hive, an online, on-demand pelvic floor fitness platform for pregnancy, postpartum, menopause, painful sex and pelvic floor strengthening. Sara lives in New Orleans with her husband and two sons. FLOORED: A Complete Guide to Women's Pelvic Floor Health at Every Age and Stage is her first book.   To connect with Sara or order her book Floored, see links at bottom of show notes.   If you want more support from me, reach out for 1:1 or group coaching, join my FREE and Private support group below and DOWNLOAD my new APP Pelvic Floor, Core & More that has my on demand 12 wk program, tracking features, pelvic floor 101 masterclass and more!    RESTORE is my first 12 wk online signature program hosted inside my new platform that will be an APP soon Pelvic Floor, Core & More! Inside that program I walk you through the basics of healing, restoring your breathing, posture, core function and overall strength and return to impact and intensity.  All with the guidance of me, a Pelvic Floor PT, in your pocket making sure that you are getting individualized support and feedback through the program during our weekly group coaching calls! This option is great for those that can't afford a one-on-one session for $200-$240, those that don't have access to a pelvic floor PT in person or those that want to have a structured organized program with support as they are phasing out of acute therapy treatments and working more independently.    

Mike Sharma, MD, MSc, FRCPC - Can We Set a New Standard of Care for Secondary Stroke Prevention? Evaluating Current Gaps and Future Goals

Join us for an engaging discussion with Chad Clary where we explore how architectural projects differ from movies and video games in terms of crediting contributors. We talk about whether the industry needs a better system for recognizing all those involved in building projects. The conversation also covers the critical importance of specificity in architectural documentation, examining how evolving professional roles affect design intent preservation while meeting contractor expectations.Episode Links:The Barnes Foundation by TWBTA-----Have a question for the hosts? Ask it at AskArchispeak.comThank you for listening to Archispeak. For more episodes please visit https://archispeakpodcast.com.Support Archispeak by making a donation.

Learn how your treatment plan is decided and terms you may seeWe continue our series to help you understand cancer and its treatment. This week we focus on surgery, the oldest form of cancer treatment. Learn about surgery timing, types of cancer surgery, and how NCCN evidence-based guidelines provide a standard treatment path no matter where you are.In this Episode:02:58 - Wisconsin-Cheese, UFOs, and Booyah Stew04:52 - Anna Quindlen: Get a Life Where You Are Generous"08:06 - Medical Specialists Involved in Cancer Care08:52 - Treatment Decisions, Tumor Board and NCCN Guidelines12:03 - Adjuvant and Neoadjuvant Therapy13:13 - Surgery Timing, Reasons and Types18:00 - Discussion - NCCN and Role of Research24:34 - Reeves Keyworth:“On Loved Ones Telling the Dying to ‘Let Go”23:54 - OutroSurgery, radiation therapy, and chemotherapy alone or in combination are the most-common methods used to treat cancer. Specific treatment varies depending on the kind of cancer, the extent of the disease, its rate of progression, and the condition of the person. Surgery alone may not result in a cure and often chemotherapy and/or radiation are needed after surgery. Learn all about surgery and the guidelines your doctor will be following for your treatment.Support the showGet show notes and resources at our website: every1dies.org. Facebook | Instagram | YouTube | mail@every1dies.org

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/MFK865. CME/AAPA credit will be available until March 10, 2026.Leveling the Standard of Care in Hemophilia A: Insights & Strategies for Developing Effective, Personalized Treatment Plans In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/MFK865. CME/AAPA credit will be available until March 10, 2026.Leveling the Standard of Care in Hemophilia A: Insights & Strategies for Developing Effective, Personalized Treatment Plans In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/MFK865. CME/AAPA credit will be available until March 10, 2026.Leveling the Standard of Care in Hemophilia A: Insights & Strategies for Developing Effective, Personalized Treatment Plans In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/MFK865. CME/AAPA credit will be available until March 10, 2026.Leveling the Standard of Care in Hemophilia A: Insights & Strategies for Developing Effective, Personalized Treatment Plans In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/MFK865. CME/AAPA credit will be available until March 10, 2026.Leveling the Standard of Care in Hemophilia A: Insights & Strategies for Developing Effective, Personalized Treatment Plans In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/MFK865. CME/AAPA credit will be available until March 10, 2026.Leveling the Standard of Care in Hemophilia A: Insights & Strategies for Developing Effective, Personalized Treatment Plans In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/MFK865. CME/AAPA credit will be available until March 10, 2026.Leveling the Standard of Care in Hemophilia A: Insights & Strategies for Developing Effective, Personalized Treatment Plans In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.Disclosure information is available at the beginning of the video presentation.

Judy and Dennis (TheVascular Guy) discuss the importance of patient-centered care, the challenges of managing patients with sensitive skin sensitivities, and the need for alternative solutions like Covalon's dressings. They also explore the potential trend of increased skin sensitivity, the use of chlorhexidine and silicone-based dressings for patient care, and the importance of thorough patient assessment and providing multiple treatment options. The duo conclud by discussing the challenges of implementing cultural and administrative changes in healthcare systems, the importance of patch testing with products, and the need for improved practices in managing catheters.Thank you to Covalon for sponsoring this Podcast! www.covalon.comSupport the show

Welcome to the Oncology Brothers podcast! In this episode, Drs. Rahul and Rohit Gosain are joined by Dr. Kevin Kalinsky, a leading breast medical oncologist and director of the breast cancer program at the Winship Cancer Institute of Emory University. Join us as we dive deep into the complexities of hormone receptor-positive breast cancer treatment. We discuss the latest advancements in treatment algorithms, including the use of OncotypeDX in premenopausal versus postmenopausal women, the role of ovarian function suppression, and the implications of new approvals like Inavolisib and CDK4-6 inhibitors. Key topics covered in this episode: •⁠  ⁠The significance of recurrence scores in dictating adjuvant chemotherapy •⁠  ⁠The ongoing OFSET trial and its potential impact on treatment decisions •⁠  ⁠Insights into the use of genomic assays like MammaPrint and RS-Clin •⁠  ⁠The evolving landscape of treatment options for locally advanced and metastatic breast cancer •⁠  ⁠The latest on PARP inhibitors, T-DXd, and other novel therapies Whether you're a medical professional or someone interested in the latest in oncology, this episode is packed with valuable insights and clinical pearls. Don't forget to subscribe for more discussions on cancer treatment, FDA approvals, and conference highlights! YouTube: https://youtu.be/_icBN3J3Bc0 Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers #OncologyBrothers #HR+ #breastcancer   #HormoneReceptorPositiveCancer #oncbrothers  #Podcast

This podcast was edited on a plane ride to Japan, and the intro was recorded in a bathroom while my kids slept off the jet lag. It's still good. I recently went down with Ben Greenzweig, the Executive Director of the non-profit Living Water Brain Treatment Center in Myrtle Beach, South Carolina. We are—right now—providing TMS treatment and, soon to be more, in a local community in Ben's beloved home of Horry County. There are 400,000 residents and less than 30 psychiatric inpatient beds in the county. There are not enough services to meet the needs he saw in his community—so he started Living Water to help. I'll remind readers that not only did he write an article about it, but he is also running a non-profit. Thus, consider donating.The audio from today's podcast was recorded mainly on my phone, which I had in my pocket as I gave the talk. Please share it with friends. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit thefrontierpsychiatrists.substack.com/subscribe

Dr Evelyn Ainsley McWilliams joins Ethics Talk to discuss her article, coauthored with Dr Lisa Bayer: “How Should Intensity and Duration of Pain Inform Standard of Care for Pain Management in Non-Labor and Delivery OB/GYN Procedures?”  Recorded December 3, 2024.  Read the full article for free at JournalOfEthics.org

Be sure to tune in to this episode of the Precision Health and PGX Podcast as Dr. Becky Winslow, and Dr. Angela Cassano, PharmFusion Founder and owner, discuss Dr. Cassano's personal pharmacogenomics testing and how the results impacted her breast cancer treatment, the tamoxifen and CYP2D6 pharmacogenomics clinical utility research currently available, whether CYP2D6 testing for patients prior to tamoxifen is National Comprehensive Cancer Network (NCCN) and American Society of Clinical Oncology (ASCO) recommended, and whether insurers in the United States reimburse the testing. This is a must listen for those interested in the clinical pharmacogenomics' current landscape and a pharmacist-patient's perspective about PGx testing.   

Be sure to tune in to this episode of the Precision Health and PGX Podcast as Dr. Becky Winslow, and Dr. Angela Cassano, PharmFusion Founder and owner, discuss Dr. Cassano's personal pharmacogenomics testing and how the results impacted her breast cancer treatment, the tamoxifen and CYP2D6 pharmacogenomics clinical utility research currently available, whether CYP2D6 testing for patients prior to tamoxifen is National Comprehensive Cancer Network (NCCN) and American Society of Clinical Oncology (ASCO) recommended, and whether insurers in the United States reimburse the testing. This is a must listen for those interested in the clinical pharmacogenomics' current landscape and a pharmacist-patient's perspective about PGx testing.   

This episode is a continuation of last week. It focuses on both the positive and negative medical experiences of people who have gone through infertility and loss. People wrote in and sent clips sharing about either a medical provider that was extremely helpful and supportive or one that was not supportive and needs improvement. Listen as they share their experiences and show there is no true standard of care when it comes to infertility or pregnancy and infant loss.

This episode focuses on both the positive and negative medical experiences of people who have gone through infertility and loss. People wrote in and sent clips sharing about either a medical provider that was extremely helpful and supportive or one that was not supportive and needs improvement. Listen as they share their experiences and show there is no true standard of care when it comes to infertility or pregnancy and infant loss.

Send us a textThe Modern Urologist Podcast has launched a new miniseries, Precision Oncology and Prostate Cancer: The New Standard of Care, hosted by Dr. Paul Sieber and Ashleigh Renitsky, Oncology PA. This series will focus on the evolving role of genetic testing in prostate cancer care and its impact on personalized patient treatment plans.Episode #1 - Genetic testing basicsThe first installment will provide an overview of genetic testing, highlighting the difference between germline and somatic testing, and their implications for personalized treatment. This episode emphasizes the importance of integrating streamlined testing protocols into clinical practice, understanding test results to tailor therapies for patients, and leveraging genetic counselors. 

What is the standard of care? It's not a single document like the Declaration of Independence, so what is it and who decides what it is? In this episode Andrew talks through a few resources to help you find, establish, and implement the dental standard of care in your offices. He also gives a strong warning the the RDH profession... Resources: Https://www.perio.org Https://aap.org https://aacariology.org/about/

Dr. Linda Duska and Dr. Domenica Lorusso discuss the practice-changing results of the phase 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18 study, which evaluated pembrolizumab plus chemoradiotherapy as treatment for previously untreated, high-risk, locally advanced cervical cancer. TRANSCRIPT  Dr. Linda Duska: Hello, I'm Linda Duska, your guest host of the ASCO Daily News Podcast today. I'm a professor of obstetrics and gynecology and serve as the associate dean for clinical research at the University of Virginia School of Medicine. On today's episode, we'll be discussing a new standard of care for previously untreated, high- risk locally advanced cervical cancer. This follows the ENGOT-cx11/GOG-3047/KEYNOTE-A18 study, which I will be referring to as KEYNOTE-A18 for the rest of this podcast, which demonstrated that pembrolizumab plus chemoradiotherapy improved both progression-free and overall survival compared to chemoradiotherapy alone. I was a co-author of this study, and I'm delighted to be joined today by the study's lead investigator, Dr. Domenica Lorusso, for today's discussion. She is also a professor of obstetrics and gynecology. She's at Humanitas University Rosano and the director of the Gynecologic Oncology Unit at the Humanitas Hospital San Pio in Milan, Italy. Our full disclosures are available in the transcript of this episode. Dr. Lorusso, it's great to be speaking with you today. Dr. Domenica Lorusso: Thank you, Linda. It's a great pleasure to be here. Thank you. Dr. Linda Duska: So I was hoping you could start us out with some context on the challenges associated with treating patients with high-risk, locally advanced cervical cancer. Dr. Domenica Lorusso: Yes. I have to make a disclosure because in my experience as a gynecologist, cervical cancer patients are the most difficult patients to treat. This is a tumor that involves young patients [who often have] small kids. This is a very symptomatic tumor. More than 50% of patients report pain. Sometimes the pain is difficult to control because there is an infiltration of the pelvic nerves and also a kind of vaginal discharge, so it's very difficult to treat the tumor. Since more than 25 years, we have the publication of 5 randomized trials that demonstrate that when we combine platinum chemotherapy to radiation treatment, we increase overall survival by 6%. This is the new standard of care – concurrent chemoradiation plus brachytherapy. This is a good standard of care because particularly modern, image-guided radiotherapy has reported to increase local control. And local control in cervical cancer translates to better overall survival. So modern radiotherapy actually is able to cure about 75% of patients. This is what we expect with chemoradiation right now. Dr. Linda Duska: So what are the key takeaways of A18? This is a really exciting trial, and you've presented it a couple of times. Tell us what are the key takeaways that you want our listeners to know. Dr. Domenica Lorusso: Linda, this is our trial. This is a trial that we did together. And you gave me the inspiration because you were running a randomized phase 2 trial exploring if the combination of pembrolizumab to concurrent chemoradiation was able to give signals of efficacy, but also was feasible in terms of toxicity. There were several clinical data suggesting that when we combine immunotherapy to radiotherapy, we can potentially increase the benefit of radiotherapy because there is a kind of synergistic effect between the two strategies. Radiotherapy works as a primer and immunotherapy works better. And you demonstrated that it was feasible to combine immunotherapy to concurrent chemoradiation. And KEYNOTE-A18 was based on this preliminary data. We randomized about 1,060 patients to receive concurrent chemoradiation and brachytherapy or concurrent chemoradiation and brachytherapy in combination with pembrolizumab followed by pembrolizumab for about two years. Why two years? Because in more than 80% of cases, recurrence in this patient population occurred during the first two years. So the duration of treatment was based on the idea to provide protection to the patient during the maximum time of risk. And the trial had the two primary endpoints, progression free and overall survival, and met both the endpoints, a significant 30% reduction in the risk of progression that was confirmed. At the 3-year follow up, the observation was even better, 0.68. So 32% reduction in the risk of progression. And more importantly, because this is a curative setting, 33% reduction in the risk of death was reported in the experimental arm when pembro was combined with chemoradiation. Dr. Linda Duska: That's amazing. I wanted to ask you, a prior similar study called CALLA was negative. Why do you think A18 was positive? Dr. Domenica Lorusso: Linda, there are several discussions about that. I had the possibility to discuss several times with the PI of CALLA, Brad Monk. The idea of Brad is that CALLA was negative because of using durvalumab instead of PD-1 inhibitor, which is pembrolizumab. I do not have exactly the same impression. My idea is that it's the kind of patient population enrolled. The patient population enrolled in KEYNOTE-A18 was really a high-risk population; 85% of that patient were node positive, where the definition of node positivity was at least 2 lymph nodes in the pelvis with a short diameter of 1.5. So, we are very confident this patient was node-positive, 55% at the grade 3 and 4 diseases. So this is really a high-risk population. I remember at the first presentation of CALLA, I was honored to discuss the CALLA trial when it was first presented at IGCS a few years ago. And when I received the forest plot of Calla, it was evident to me that in patients with stage III and node positive there was a signal of efficacy. And we have a huge number of patients with node positive. So in my opinion this is the reason why KEYNOTE-A18 is positive. Dr. Linda Duska: Yeah, I agree with you. I've thought about it a lot and I think you're right about that. The INTERLACE trial results were recently published. How should we interpret these results in the context of A18? Dr. Domenica Lorusso: So it's very difficult to compare the 2 trials. First of all, in terms of population. The population enrolled in INTERLACE is a low-risk, locally advanced but low risk population; 76% were stage II, 10% were stage I, 60% were node-negative patients. So, first of all, the population is completely different. Second is the type of radiotherapy that was provided. INTERLACE is a 10-year long trial, but in 10 years the quality and the technique of radiotherapy completely changed. Only 30% of patients in INTERLACE received what we call the modern image-guided brachytherapy, which is important because it provides local control and local control increases overall survival. And third, we read the paper. I'm not a methodologist, but there are some methodological biases in the paper. All the statistical design of the trial was based on PFS, but PFS was evaluated at physician description. And honestly, I never saw a trial that had no pre-specified timeline for radiological evaluation. It's very difficult to evaluate progression in cervical cancer because the fibrosis related to radiotherapy changes the anatomy in the pelvis. And I think that the radiological evaluation is important to address if the patient is progressing or not. Particularly, because the conclusion of CALLA is that the PFS was mainly in favor of distant metastasis. So really, it's difficult for me to understand how distant metastasis may be evaluated with the vagina visit. So really, it's very difficult to compare the two trials, but I have some concerns. And also because of toxicity in the study, unfortunately 30% of patients did not complete concurrent chemoradiation because of residual toxicity due to induction chemotherapy. So I wanted to be sure in the context of modern radiotherapy, if really induction chemo adds something to modern radiotherapy. Dr. Linda Duska: Well, I have two more questions for you. As we move immunotherapy into the front line, at least for these high risk locally advanced cervical cancer patients that were eligible for A18, what does that mean then for hopefully those few that develop recurrence in terms of second line therapy? Dr. Domenica Lorusso: Well, Linda, this is a very important question. We do not have data about immuno after immuno, but I would not completely exclude this hypothesis because in KEYNOTE-A18, the patient received treatment for a well-defined time period. And for those patients not progressing during immunotherapy, I really guess if there is a space for the reintroduction of immunotherapy at the time of recurrence. In this moment we have 30% of patients in KEYNOTE-A18 in the control arm that receive immunotherapy after progression, but still we have 11% of patients that receive immunotherapy in combination with concurrent chemoradiation and then receive, again, immunotherapy in later line of therapy. I think we need to collect these data to capture some signals and for sure we have the new drug. We have antibody drug conjugate. The trials are ongoing exploring the role of antibody drug conjugate, particularly in immune pretreated patients. So I think this is a very interesting strategy. Dr. Linda Duska: I was going to ask you, “What are the next steps,” but I think you already answered that question. You talked about the second line. If you were going to redesign a study in the frontline, what would it look like? Dr. Domenica Lorusso: Probably one question that I would like to answer – there are two questions in my opinion in KEYNOTE-A18 – one is induction immunotherapy. Linda, correct me if I'm wrong, you reported very interesting data about the immune landscape change when you use induction immunotherapy. And I think this is something that we need to explore in the future. And the second question is the duration of maintenance. Because, again, we decided for two years based only on the epidemiology of recurrence, but I guess if one year may be enough. Dr. Linda Duska: I think this sequencing question is really important, that the induction immunotherapy was actually GY017. I can't take credit for that, but I think you're right. I think the sequencing question is really important. Whether you need the concurrent IO or not is an important question. And then to your point about the 2 years, the length of the need for maintenance therapy is a question that we don't know the answer to. So there are lots of really important questions we can continue to ask. I want to thank you so much for sharing your valuable insights with us on the podcast today. You're always so thoughtful about this particular study and cervix cancer in general and also for your great work to advance the care for patients with GYN cancers. Dr. Domenica Lorusso: Thank you, Linda. It's our work - we progress together. Dr. Linda Duska: Yes. And we thank the patients as well. The over 1,000 patients that went on this trial during a pandemic. Right? Dr. Domenica Lorusso: Absolutely. Without their generosity and their trust, we would not be able to do this trial. Dr. Linda Duska: So we're very grateful to them and we thank our listeners for your time today. If you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review and subscribe wherever you get your podcasts. Thank you all.   Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity or therapy should not be construed as an ASCO endorsement.   Follow today's speakers:  Dr. Linda Duska @Lduska Dr. Domenica Lorusso   Follow ASCO on social media:   @ASCO on Twitter   ASCO on Facebook   ASCO on LinkedIn     Disclosures:   Dr. Linda Duska: Consulting or Advisory Role: Regeneron, Inovio Pharmaceuticals, Merck, Ellipses Pharma Research Funding (Inst.): GlaxoSmithKline, Millenium, Bristol-Myers Squibb, Aeterna Zentaris, Novartis, Abbvie, Tesaro, Cerulean Pharma, Aduro Biotech, Advaxis, Ludwig Institute for Cancer Research, Leap Therapeutics Patents, Royalties, Other Intellectual Property: UptToDate, Editor, British Journal of Ob/Gyn Dr. Domenica Lorusso: Consulting or Advisory Role: PharmaMar, AstraZeneca, Clovis Oncology, GSK, MSD, Genmab, Seagen, Immunogen, Oncoinvest, Corcept, Sutro Biopharma, Novartis, Novocure, Daiichi Sankyo/Lilly Speakers' Bureau: AstraZeneca, Clovis, GSK, MSD, ImmunoGen, Seagen Research Funding (Inst.): PharmMar, Clovis, GSK, MSD, AstraZeneca, Clovis Oncology, Genmab, Seagen, Immunogen, Incyte, Roche, Pharma&, Corcept Therapeutics, Alkermes Travel, Accommodations, Expenses: AstraZeneca, Clovis, GSK, Menarini  

In this episode, Dr. Valentin Fuster highlights the Forest HCM study, which focuses on the withdrawal of standard care medications in patients with obstructive hypertrophic cardiomyopathy receiving afficantin. The study shows promising results: nearly half of the patients who attempted to reduce or stop their medications did so successfully, with significant improvements in functional class and symptoms. While the findings suggest that afficantin may allow for the reduction of traditional therapies, caution is advised, as not all patients may benefit equally.

The WHO recently stated that fluoride is, in fact, unsafe. After 60 years of being labeled a conspiracy theory, with experts reassuring the public about its safety, people should be concerned about taking the “experts” for their word. We should be doing our own research.   Pfizer's admission that they did not test certain aspects of their COVID-19 vaccine before marketing it as "safe" and "effective" raises serious questions. Can we keep on blindly trusting "expert" advice? In this episode, Brian Moody and Hans Toohey discuss why you need to become your own expert. They delve into what you must look out for before making decisions that greatly impact your or your family's lives. Tune in to learn about what Brian and Hans do to make more informed choices about their health and lives. Be Skeptical of What the “Experts” Say: Question everything. Just because an “expert” says something, doesn't mean it's infallible. If it concerns your body or impacts your life, take the initiative to do your own research instead of blindly trusting someone simply because they hold a PhD. Throughout history, there has been "common knowledge" that experts endorsed which later proved to be incorrect. Historical Narratives Should Be Re-examined: Don't hesitate to research and consider alternative viewpoints that challenge commonly accepted historical knowledge. Understanding that history is often presented with biases, and exploring different perspectives can give you a more comprehensive and accurate understanding of past events. Corporations Don't Want You To Get Better: Pharmaceutical companies prioritize profits over the well-being of individuals. Their decisions on product development, marketing, and distribution are driven more by financial gain than by public health benefits. Critically assess medical products and treatments, weighing their pros and cons before proceeding. Trust Yourself, Not Just Experts: Take personal responsibility and trust your own judgment. Whether it's about family health, financial decisions, or general well-being, strive to become the expert in your own life. Gather information, question the norms, and make informed decisions for the benefit of your family. Got Questions? Reach out to us at info@remnantfinance.com ⁠Visit https://remnantfinance.com for more information FOLLOW REMNANT FINANCE Youtube: @RemnantFinance (https://www.youtube.com/@RemnantFinance) Facebook: @remnantfinance (https://www.facebook.com/profile?id=61560694316588) Twitter: @remnantfinance (https://x.com/remnantfinance) TikTok: @RemnantFinance Don't forget to hit LIKE and SUBSCRIBE 

I'm sharing my latest medical adventure where the standard of care medical system tried to steer me into a hysterectomy. Why? Because a biopsy indicated complex atypical hyperplasia, and despite a CT scan showing no cancer, the recommendation was a full hysterectomy. But let me tell you, I wasn't about to jump into a life-altering surgery without peeling back every layer. And let me tell you, navigating this medical maze was a shocker. I dove into all the options, from hormone therapy to biopsies every three months, determined to advocate for my health. Through my story and insights from listeners who shared LIVE their own health hurdles, I unpack the importance of being informed and proactive. So, if you've ever felt lost in the medical system, this episode is your guide to standing firm and making empowered, educated decisions about your health. Trust me, you don't want to miss this! Shop ALL of Dr. Amie's Fixxr® Supplements: betterlifedoctor.com LET'S GET YOUR LIFE BACK...Connect with Dr. Amie Hornaman Book a free application call: https://dramiehornaman.com/pages/book-a-call FREE DOWNLOADS… What Are the Optimal Lab Ranges? What Steps Can I Take? Don't know where to start...don't know which labs are useful? And what to do when you get your results? “How To” Guide For Supplements Here's your Fixxr® supplement timeline and guide. RATE, REVIEW AND FOLLOW ON APPLE PODCASTS Show your love for Amie and The Thyroid Fixer Podcast! If you're enjoying our journey together, I'd be thrilled if you could take a moment to rate and review the show on Apple Podcasts. Your support helps me reach and help more people just like you, guiding them towards their optimal selves! Just click HERE, scroll all the way down, give us those 5 stars, and share what you enjoy about my episodes in a review. Haven't subscribed yet? Make sure to follow The Thyroid Fixer Podcast to catch all the new episodes that come out every week. Follow HERE and never miss out on a moment of the journey! CONNECT WITH ME ON SOCIAL MEDIA: Join my exclusive Facebook Group, Dr. Amie…The Thyroid Fixer®...Love Your Mirror, for a Community of HOPE and Support in your thyroid journey. https://www.facebook.com/groups/dramie/ Like me on Facebook: Amie Hornaman Nutrition and Functional Medicine Subscribe on Youtube: Dr. Amie Hornaman Follow me on Instagram: @dramiehornaman

This episode is sponsored by CurvaFix®, Inc, the makers of the CurvaFix® IM Implant – Delivering strong, minimally invasive fixation for curved anatomy and poor bone. In this podcast, Brett Crist, MD moderates a conversation about the treatment of elderly patients' who sustain immobility injuries of the pelvis and acetabulum with Julie Switzer, MD and Robert Wetzel, MD. During their conversation they dive into the clinical and economic impact of the current standard of care, how their patient care has evolved over time, patient outcomes, and more! To learn more about the CurvaFix system, please visit our website: CurvaFix

The documentary I want to share with you today is called "A New Standard of Care" by Megan Smith, and it's talking about holistic approaches to healing the body from cancer.About the Host:Melissa is an Integrative Health Practitioner and Master Practitioner in NLP and Timeline Therapy and a Board Designated Hypnotherapy Teacher Trainer, helping people get to the root cause of their health issues and then get lasting results. Melissa neither diagnoses nor cures but helps bring your body back into balance by helping discover your “toxic load” and then removing the toxins. Melissa offers functional medicine lab testing that helps you “see inside” to know exactly what is going on, and then provides a personalized wellness protocol using natural herbs and supplements. Melissa's business is 100% virtual – the lab tests are mailed directly to your home and she specializes in holding your hand and guiding the way to healing so that you don't have to figure it all out on your own.Melissa is the winner of the 2021 & 2022 Quality Care Award by Business From The Heart and is also the recipient of the Alignable “Local Business Person of the Year “Award 2022 for Whistler.Melissa has been featured at a number of Health & Wellness Summits, such as the Health, Wealth & Wisdom Summit, The Power To Profit Summit, The Feel Fan-freaking-tas-tic Summit, the Aim Higher Summit and many more! She has also guested on over 60 different podcasts teaching people about the importance of prioritizing our health and how to get started. Linktree: https://linktr.ee/yourguidedhealthjourney Thanks for listening!If you know somebody who would benefit from this message, or would be an awesome addition to our community, please share it using the social media buttons on this page.Do you have some feedback or questions about this episode? Leave a note in the comment section below! Subscribe to the podcast!If you would like to get automatic updates of new podcast episodes, you can subscribe on the podcast app on your mobile device.

Sodium-glucose cotransporter-2 (SGLT-2) inhibitors are one of the established treatments used to slow the progression of CKD and improve outcomes.  Could perhaps the glucagon-like peptide 1 (GLP-1) receptor agonists provide similar, additive, or different benefits in patients with CKD?  Guest Author: John Swegle, PharmD, BCPS, BCACP  Music by Good Talk

In this episode of The Standard of Care Podcast, Samantha Johnson and Nick Adams recount their journey from attending conferences to becoming conference speakers on critical medical-legal topics in EMS. They reflect on how these pivotal experiences shaped their current work. The episode dives into highlights from recent EMS conferences, such as South Carolina EMS, Metro Atlanta EMS, and FAST24, where they engaged with street-level medics and addressed critical topics in the ever-evolving landscape of EMS law. Whether you're a seasoned provider or just starting, this episode offers valuable takeaways on the value of EMS conferences, the evolution of the Standard of Care Podcast, and the importance of staying informed and involved in industry developments. Links:National Association of EMS Physicianshttps://naemsp.org/2025 Annual MeetingJanuary 6-11, 2025https://naemsp.org/annual-meeting/ South Carolina EMS Associationhttps://scemsa.org/2025 SCEMSA SymposiumMarch 5-7, 2025https://scemsa.org/ems-symposium Metro Atlanta EMS Conference2025 Metro Atlanta EMS Conference January 30-31, 2025https://www.maemsc.org/ Prisma Health Swamp Rabbit Prehospital Medicine Conference2025 Swamp Rabbit Conference June 17-19, 2025https://www.facebook.com/ghsemsconference/ FAST25(FlightBridgeED Air and Surface Transport Symposium 2025)Lexington, KY | May 19-21, 2025https://fbefast.com FTFC/Gathering of Eagles2025 FTFC/Gathering of Eagles June 9-13, 2025https://firsttherefirstcare.com/ 

Returning guest, Grace's dad Scott Schara chats with Crash Connell. Grace's dad walks through how Standards of Care were designed to kill us and the only solution. He also gives us an update on the lawsuit surrounding Grace's wrongful death. Links: https://ouramazinggrace.net https://rumble.com/c/c-2054162   Stand Up For The Truth's Rumble Page: https://rumble.com/user/CTRNOnline Donate to our Truth mission: https://www.standupforthetruth.com/donate/

Returning guest, Grace's dad Scott Schara chats with Crash Connell. Grace's dad walks through how Standards of Care were designed to kill us and the only solution. He also gives us an update on the lawsuit surrounding Grace's wrongful death. Links: https://ouramazinggrace.net https://rumble.com/c/c-2054162   Stand Up For The Truth's Rumble Page: https://rumble.com/user/CTRNOnline Donate to our Truth mission: https://standupforthetruth.com/donate/

This episode is brought to you by Cozy Earth, Maui Nui, and Lumebox. We've heard about Dr. Thomas Seyfried's groundbreaking research and approach to cancer as a disease of metabolic dysfunction. Today's guest was inspired by Dr. Seyfried's metabolic approach and conducted his own research on brain cancer cells using ketone-based metabolic therapy and hyperbaric oxygen. His findings were mind-blowing! Today on The Dhru Purohit Podcast, Dhru sits down with Dr. Dominic D'Agostino to discuss his extensive research on brain cancer cells placed in ketosis and under the pressure of hyperbaric oxygen. Dr. D'Agostino shares why his findings provide further insight into the idea that cancer cell growth can be metabolically managed. He also discusses how exercise and a low-carbohydrate diet can be used as metabolic therapies to reduce cancer risk. Dr. D'Agostino shares the critical tests we should focus on to assess our metabolic health and the essential supplements that can support ketosis.  Dr. Dominic D'Agostino is an Assistant Professor at the University of South Florida College Of Medicine, Molecular Pharmacology & Physiology, where he develops and tests metabolic therapies, including alternative energy substrates and ketogenic agents for neurological disorders, cancer, and wound healing. While studying the effects of gasses on the brains of Navy Seal divers, he developed an approach for metabolically starving cancer cells through diet and compressed oxygen, replacing chemotherapy, surgery, or radiation.   In this episode, Dhru and Dr. D'Agostino dive into (audio version / Apple Subscriber version): The most innovative approaches to cancer (00:00:11 / 00:00:11)  The metabolic approach to cancer (1:30/1:30) Using the hyperbaric approach in cancer patients (13:00/ 9:03) The results of Dr. A'gostino's studies on mice (17:00 / 13:50) How this research translates to patients (22:00 / 18:05) Why a ketogenic diet can be therapeutic (37:00 / 32:04) The role of exercise in cancer prevention (53:00 / 46:35) What lifestyle factors should we be doubling down on for prevention (55:00 / 50:14) Dr. D'Agostino's thoughts on a low carbohydrate diet (1:01:00 / 56:30) The therapeutic benefits of ketosis (1:11:00 / 1:06:40) Supplements that can support ketosis (1:19:00 / 1:12:43) How to measure for ketosis (1:24:00 / 1:18:30) Checking the status of your metabolic health (1:26:00 / 1:21:30) Where to find community (1:34:00 / 1:28:16) Also mentioned in this episode: Keto Start Donate to the University of Florida (Metabolic Therapy and Cancer Research #250244) Levels  To learn more about Dr. D'Agostino, follow him on Instagram, Twitter, or his website.  Right now, get 40% off your Cozy Earth sheets. Just head over to cozyearth.com and use code DHRUP. Right now, Maui Nui Venison is offering my community 20% off your first purchase. Just go to mauinuivenison.com/DHRU or enter the code D-H-R-U at check out to get 20% off and up your high-quality protein today. Lumebox is offering my community $260 off their FDA-approved portable Red Light device! That's over 40% off! Go to thelumebox.com/dhru and get your Red Light device.